{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T15:29:33Z","timestamp":1771687773918,"version":"3.50.1"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T00:00:00Z","timestamp":1389225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0082209","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T21:32:25Z","timestamp":1389303145000},"page":"e82209","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["A Phase I, Dose-Finding Study of Sorafenib in Combination with Gemcitabine and Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Grupo Espa\u00f1ol Multidisciplinario en C\u00e1ncer Digestivo (GEMCAD) Study"],"prefix":"10.1371","volume":"9","author":[{"given":"Jorge","family":"Aparicio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Garc\u00eda-Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma Lourdes","family":"Petriz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Feliu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma Elena","family":"S\u00e1nchez-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Ram\u00f3n","family":"Ayuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Conill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Maurel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,1,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1200\/JCO.2006.07.5663","article-title":"Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies","volume":"25","author":"F Huguet","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.2006.09.2551","article-title":"Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer","volume":"25","author":"A Sultana","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"T Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"ref4","first-page":"2246","article-title":"Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma","volume":"7","author":"RA Wolff","year":"2001","journal-title":"Clin Cancer Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1200\/JCO.2001.19.22.4202","article-title":"Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer","volume":"19","author":"CJ McGinn","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/jcp.21753","article-title":"Role of RAF\/MEK\/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines","volume":"220","author":"P Ulivi","year":"2009","journal-title":"J Cell Physiol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0360-3016(95)02134-5","article-title":"Radiosensitization of pancreatic cancer cells by 20,20-difluoro-20-deoxycytidine","volume":"34","author":"TS Lawrence","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1634\/theoncologist.12-4-465","article-title":"Design of clinical trials of radiation combined with antiangiogenic therapy","volume":"12","author":"S Senan","year":"2007","journal-title":"The Oncologist"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors","volume":"50 Suppl 1","author":"RL Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"9443","DOI":"10.1158\/0008-5472.CAN-07-1473","article-title":"Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation","volume":"67","author":"JP Plastaras","year":"2007","journal-title":"Cancer Res"},{"key":"ref11","first-page":"3S","article-title":"Phase I study of sorafenib and SBRT for advanced hepatocellular carcinoma","volume":"84","author":"LA Dawson","year":"2012","journal-title":"I J Rad Biol Phys"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s10637-012-9916-5","article-title":"A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study","author":"NK LoConte","year":"2013","journal-title":"Invest New Drugs"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/annonc\/mds135","article-title":"BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer","author":"A Gon\u00e7alves","year":"2012","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/0008-5472.CAN-08-4765","article-title":"PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers","volume":"69","author":"S Wee","year":"2009","journal-title":"Cancer Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/0008-5472.CAN-11-0908","article-title":"STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis","volume":"71","author":"RB Corcoran","year":"2011","journal-title":"Cancer Res"},{"key":"ref16","first-page":"2385","article-title":"Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells","volume":"16","author":"K-H Lim","year":"2006","journal-title":"Cancer Biology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/0008-5472.CAN-10-1517","article-title":"Activation and involvement of Ral GTPases in colorectal cancer","volume":"71","author":"TD Martin","year":"2011","journal-title":"Cancer Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1158\/0008-5472.CAN-09-2684","article-title":"Protein kinase Cl is required for pancreatic cancer cell transformed growth and tumorigenesis","volume":"70","author":"ML Scotti","year":"2010","journal-title":"Cancer Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","article-title":"Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)","volume":"28","author":"HL Kindler","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(11)70004-3","article-title":"Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study","volume":"12","author":"HL Kindler","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref21","article-title":"Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial","volume":"Oct 3","author":"PJ Loehrer Sr","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijrobp.2010.02.030","article-title":"MS Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer","volume":"80","author":"W Small Jr","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-09-1004","article-title":"Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells","volume":"9","author":"S Huang","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean G, Infante JR, <etal>et al<\/etal>.. (2013) Randomized Phase III Study of Weekly <italic>nab<\/italic>-Paclitaxel plus Gemcitabine vs Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas (MPACT). ASCO GI [abstract LBA148].","DOI":"10.1200\/jco.2013.31.4_suppl.lba148"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1470-2045(13)70021-4","article-title":"Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomized, phase 2 trial","volume":"14","author":"S Mukherjee","year":"2013","journal-title":"Lancet Oncol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0082209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T07:02:41Z","timestamp":1565074961000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0082209"}},"subtitle":[],"editor":[{"given":"Salomon M.","family":"Stemmer","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,1,9]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0082209","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,9]]}}}